Avastin market seen rising to $11.27 million by 2030

The global Avastin (bevacizumab) market is projected to keep growing as cancer cases rise, healthcare spending increases and biosimilars expand access. The Business Research Company says the market is set to move from $8.43 million in 2026 to $11.27 million by 2030.

Why it matters: - Avastin remains a widely used oncology biologic because it blocks VEGF and can slow tumor blood-vessel growth. - Rising cancer incidence and broader access to treatment are expanding the market for bevacizumab and related biosimilars. - Growth in healthcare spending can improve patient access to high-cost cancer drugs through insurance coverage and reimbursement.

What happened: - The Business Research Company released its Global Avastin (Bevacizumab) Market Report 2026, covering market size, trends and forecasts through 2035. - The report says the Avastin market will grow from $7.82 million in 2025 to $8.43 million in 2026. - The report projects the market will reach $11.27 million by 2030. - North America held the largest share of the Avastin market in 2025. - The report also covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report includes expanded strategic intelligence tools such as market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards and market hotspots infographics.

The details: - Avastin (bevacizumab) is a monoclonal antibody that targets vascular endothelial growth factor, or VEGF. - The drug disrupts angiogenesis, the process tumors use to form new blood vessels for oxygen and nutrients. - Avastin is used with chemotherapy to treat colorectal cancer, lung cancer, kidney cancer and glioblastoma. - The market's recent growth reflects clinical validation of VEGF inhibition, expanding label approvals, strong oncologist familiarity and early adoption in colorectal cancer. - Future growth is tied to the rise of bevacizumab biosimilars, a larger oncology patient pool, greater use in emerging markets, demand for lower-cost biologics and optimized combination regimens. - The report says the market's 2025-2030 CAGR is 7.5%. - Macmillan Cancer Support reported in August 2024 that more than 3 million people in the UK were living with cancer in 2024. - Macmillan Cancer Support expects that number to rise to 3.5 million in 2025, 4 million in 2030 and 5.3 million in 2040. - The UK Office for National Statistics reported in May 2024 that healthcare spending rose 5.6% nominally from 2022 to 2023. - The Office for National Statistics said that followed 0.9% growth in the prior year.

Between the lines: - The forecast points to a mature cancer-drug market that is still growing, but at a pace shaped by biosimilar competition and cost pressure. - The regional lead for North America suggests established oncology infrastructure and strong uptake still matter more than sheer population size. - The report's inclusion of analytics tools signals that buyers are looking for more than a market estimate; they want decision support around where growth is likely to come from.

What's next: - The market is likely to benefit most from broader biosimilar adoption and continued use in combination therapy settings. - Emerging markets could become a bigger growth engine if access and affordability improve. - The Business Research Company is positioning its 2026 report series around updated graphics, dashboards and trend analysis for planning and investment decisions.

The bottom line: - Avastin's market is still expanding, but the next phase of growth depends on how well higher cancer demand and lower-cost biosimilars offset pricing pressure.